Credit: CC0 Public Domain The U.S. Food and Drug Administration’s controversial decision to approve aducanumab for the medication of Alzheimer’s disease raises now not less…
An FDA advisory committee voted overwhelmingly in opposition to the information offered about the controversial Alzheimer’s drug candidate aducanumab Friday. The agency’s Peripheral and Central…